Leuprolide
A synthetic GnRH superagonist that paradoxically shuts down sex-hormone production by desensitizing the pituitary, producing medical castration levels of testosterone and estrogen.
Leuprolide (leuprorelin; Lupron) is a synthetic nonapeptide GnRH agonist (D-Leu6, des-Gly10-GnRH ethylamide) engineered as a superagonist of the gonadotropin-releasing hormone receptor. Continuous, non-pulsatile receptor occupation causes pituitary desensitization and receptor downregulation, suppressing LH and FSH and driving testosterone and estrogen to castrate/postmenopausal levels within 2-4 weeks. This reversible chemical hypogonadism underpins its FDA-approved use across hormone-sensitive conditions including advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.
Class
Synthetic nonapeptide GnRH (LHRH) agonist
Routes
Subcutaneous, Intramuscular, Implant/depot
Category
Hormone & Reproductive
Researched benefits
What it's studied for
Androgen deprivation for prostate cancer
By suppressing LH and driving testosterone to castrate levels, leuprolide serves as first-line androgen deprivation therapy for advanced prostate cancer. A landmark NEJM RCT showed 86% objective response, equivalent to diethylstilbestrol but with far fewer cardiovascular adverse events.
Estrogen suppression for endometriosis and fibroids
Continuous GnRH agonism reduces estrogen to postmenopausal levels, shrinking hormone-sensitive endometriotic lesions and uterine fibroids. This chemical hypogonadism forms the basis for its approved gynecologic indications.
Treatment of central precocious puberty
Long-acting depot leuprolide halts premature activation of the HPG axis in children, allowing improved final adult height outcomes; cohort data in girls showed roughly half exceeding their genetically predicted mid-parental height.
HPG axis modulation and controlled suppression
Leuprolide provides reversible, titratable suppression of the hypothalamic-pituitary-gonadal axis, making it a research tool and clinical instrument for testosterone suppression and GnRH axis control.
Combination therapy platform
In the EMBARK trial, leuprolide combined with enzalutamide improved overall survival and efficacy over leuprolide alone in high-risk biochemically recurrent prostate cancer while maintaining quality of life.
Mechanism
How it works
Leuprolide is a superagonist of the gonadotropin-releasing hormone (GnRH/LHRH) receptor. Endogenous GnRH is released in pulses, which is required to maintain normal LH and FSH secretion from the anterior pituitary. Leuprolide binds the same receptor but, given continuously rather than in pulses, produces sustained non-physiologic receptor occupation.
This continuous stimulation initially triggers a transient surge, or 'flare,' in LH, FSH, and downstream testosterone or estrogen. Within days to weeks, however, the sustained agonism causes receptor downregulation and pituitary desensitization, the opposite of the endogenous pulsatile signal. LH and FSH secretion collapse, and sex-steroid production falls to castrate levels in men and postmenopausal levels in women, typically within 2-4 weeks.
The resulting reversible chemical hypogonadism is the therapeutic mechanism across all indications: it starves hormone-sensitive prostate cancer of testosterone, shrinks estrogen-dependent endometriosis and fibroids, and halts the premature HPG-axis activation of central precocious puberty. Because the effect is driven by receptor desensitization rather than permanent damage, hormone production generally recovers after therapy is stopped.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Clinical (prostate cancer, pivotal trial)
- Dose
- 1 mg
- Frequency
- Once daily
- Timing
- Consistent daily dosing
- Duration
- Continuous per oncology protocol
- Route
- Subcutaneous
Dose used in the landmark NEJM phase 3 trial that achieved 86% objective response in metastatic prostate cancer.
Depot (maintenance)
- Dose
- Monthly or multi-month depot
- Frequency
- Every 1, 3, 4, or 6 months depending on formulation
- Timing
- Scheduled clinic visits
- Duration
- Long-term per indication
- Route
- Intramuscular or subcutaneous depot
Depot formulations replace daily injections and are the standard for prostate cancer, endometriosis, fibroids, and precocious puberty.
Central precocious puberty
- Dose
- Monthly depot (weight/protocol based)
- Frequency
- Monthly
- Timing
- Pediatric endocrinology schedule
- Duration
- Until appropriate age to resume puberty
- Route
- Intramuscular depot
A 40-minute post-injection LH measurement can be used for diagnosis and treatment monitoring where GnRH stimulation testing is unavailable.
- Leuprolide is a prescription-only, high-risk agent that requires professional oversight and monitoring; it is not suitable for self-administration.
- Testosterone should be monitored during therapy: rare primary LHRH-agonist resistance has been reported, where testosterone fails to fall and an LHRH antagonist (e.g., degarelix) may be substituted.
- An initial hormonal 'flare' occurs before suppression; in prostate cancer this may require anti-androgen co-treatment to prevent tumor flare.
- Formulation and interval (daily injection vs monthly/multi-month depot) are selected by the treating clinician based on indication.
Evidence
Research & clinical studies (9)
Leuprolide versus diethylstilbestrol for metastatic prostate cancer
In 199 patients, leuprolide 1 mg/day subcutaneous achieved 86% objective response (vs 85% for DES) with significantly fewer adverse events, establishing GnRH agonism as the preferred androgen deprivation strategy.
PMID 6436700Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice
Enzalutamide combined with leuprolide improved overall survival and efficacy over leuprolide alone in high-risk biochemically recurrent prostate cancer while maintaining quality of life.
PMID 42333826Surpassing genetic height potential at final adult height after monthly depot leuprolide therapy in Taiwanese girls with central precocious or early puberty: a ROC-based analysis
Roughly half of girls treated with monthly depot leuprolide for central precocious puberty achieved final adult heights exceeding their genetically predicted mid-parental height, with earlier treatment favoring better outcomes.
PMID 42130798Utility of a 40-minute LH level after depot leuprolide for diagnosis and treatment monitoring in girls with CPP
An LH level measured 40 minutes after leuprolide injection provided diagnostic accuracy comparable to the standard GnRH stimulation test, offering a practical monitoring alternative in central precocious puberty.
PMID 42189483Sterile abscesses during GnRH agonist therapy for central precocious puberty: a case series and literature review
Sterile injection-site abscesses occurred in a small percentage of children on long-acting GnRH agonists including leuprolide, and topical corticosteroids offered a conservative management option while continuing therapy.
PMID 42333572Interstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system
Analysis of FDA adverse-event reports (2003-2024) linked leuprolide to interstitial lung disease reports, particularly in female breast cancer patients, though the signal was not unique within the drug class.
PMID 42154420Terazosin as a Non-Hormonal Treatment for Endometriosis
In a rat model, terazosin reduced inflammatory and oxidative markers in endometriotic lesions comparably to leuprolide but without hormonal suppression, suggesting a potential non-hormonal alternative.
PMID 42123670Effects of Surgical and Medical Androgen Deprivation on Bladder Remodeling and Steroid Receptor Expression: An Experimental Rat Study
In rats, medical androgen deprivation with leuprolide altered bladder remodeling and steroid receptor expression, informing understanding of androgen deprivation effects on lower urinary tract tissue.
PMID 42233452Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature
A metastatic prostate cancer patient showed rare primary resistance to leuprolide with rising testosterone despite adherence; switching to the LHRH antagonist degarelix achieved suppression, underscoring the need for testosterone monitoring.
PMID 42159776Combinations
Stacking & blends
Leuprolide + Enzalutamide
Improved outcomes in high-risk biochemically recurrent prostate cancer
Adding the androgen-receptor inhibitor enzalutamide to leuprolide-based androgen deprivation improved overall survival and efficacy versus leuprolide alone in the EMBARK trial while preserving quality of life.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active cancer history (requires specialist oversight)
- Cardiovascular conditions
- Thyroid conditions
- Pregnancy or nursing
Leuprolide carries a higher risk profile and is not suitable for self-administration without professional oversight. Testosterone should be monitored, as rare primary LHRH-agonist resistance has been documented. Consult a qualified healthcare professional before any use.
FAQ
Leuprolide — common questions
What is leuprolide?
Leuprolide (leuprorelin; Lupron) is a synthetic nonapeptide GnRH agonist (D-Leu6, des-Gly10-GnRH ethylamide) engineered as a superagonist of the GnRH receptor. Its continuous, non-pulsatile receptor occupation desensitizes the pituitary and downregulates the receptor, producing medical castration levels of testosterone in men and postmenopausal estrogen levels in women within 2-4 weeks.
Why does a GnRH agonist suppress hormones instead of raising them?
Normal GnRH is released in pulses to maintain LH and FSH. Leuprolide occupies the receptor continuously, which after an initial flare causes receptor downregulation and pituitary desensitization, collapsing LH/FSH and sex-steroid production, the opposite of the pulsatile physiologic signal.
What is leuprolide used for?
It is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty, along with other hormone-sensitive conditions. Its research areas include HPG axis modulation, testosterone suppression, hormonal restart, and GnRH axis control.
How is leuprolide administered?
It is given by subcutaneous or intramuscular injection or as an implant/depot. Options range from daily subcutaneous injection to monthly and multi-month depot formulations chosen by the treating clinician based on indication.
What does the strongest evidence show?
The pivotal 1984 NEJM phase 3 RCT of 199 patients found leuprolide 1 mg/day achieved an 86% objective response in metastatic prostate cancer, equivalent to diethylstilbestrol but with significantly fewer cardiovascular and other adverse events, establishing GnRH agonism as the preferred androgen deprivation strategy.
What are the main safety concerns?
Leuprolide is a high-risk, prescription-only agent. Reported considerations include active cancer history, cardiovascular and thyroid conditions, and pregnancy or nursing. Side effects can include an initial hormonal flare, hot flashes, bone loss, injection-site reactions, and rare interstitial lung disease reports. Professional oversight is essential.
Can leuprolide ever fail to suppress testosterone?
Rarely. A documented case report describes primary LHRH-agonist resistance where testosterone rose despite proper leuprolide use; switching to the LHRH antagonist degarelix achieved suppression. This is why testosterone monitoring is recommended during therapy.
